



## Financial/Non-Financial Highlights


### Revenue




### Adjusted operating margin\*2




### Adjusted EPS\*2




### Shareholder returns




### Colorectal cancer related training in target emerging countries and regions




### Colorectal cancer related online/hybrid training provided with HCPs globally



### Eligible male employees in Japan\*3 take parental leave



### Greenhouse gas emissions (Scope 1, 2\*4)



Note: Figures for revenue, adjusted operating margin, and adjusted EPS represent the amount of continuing operations excluding sales of the Scientific Solutions Business and the Orthopedic Business.

\*1 Calculated with constant currency basis starting from fiscal year 2023

\*2 Adjusted for extraordinary items

• Exclude "Other income / expenses"

• No adjustment will be made for the impact of exchange rate fluctuations; actual exchange rate will be used.

\*3 Eligible male employees of Olympus Corporation taking parental leave

\*4 Scope 1: Greenhouse gas emission from direct on-site use of fossil fuels.

Scope 2: Greenhouse gas emission from on-site secondary use, such as electric power purchase.

\*5 Carbon neutrality refers to reducing greenhouse gas emissions from site operations (Scope 1 and 2) and offsetting an amount equivalent to the remaining greenhouse gas emissions using carbon credits, thereby achieving zero emissions overall.